For how we live.
A single-centre randomised trial found that three cycles of intravenous immunoglobulin on top of high-dose steroids improved muscle disease faster and further — in just 44 patients, at one Dutch hospital.
The phase 3 VALOR trial met its primary endpoint at the higher dose of the oral TYK2-JAK1 inhibitor, with more serious infections — a benefit and a safety signal that arrive together.
Dazukibart eased skin and muscle disease within weeks and held up for nearly two years — but the trials were tiny, manufacturer-run, and the makers say a phase 3 is needed to confirm it.